# Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Source: https://onco.cc/trials/nct07284433/  
OnCo record `nct07284433` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Allo-QuadCAR01-T in diffuse large B-cell lymphoma and non-Hodgkin lymphoma, run by AvenCell Therapeutics, Inc., now recruiting.

## Summary

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT07284433 by AvenCell Therapeutics, Inc., with 178 participants planned, started 2026-01-06 and due to reach its primary completion in 2029-04-27. Interventions recorded: Allo-QuadCAR01-T.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07284433
- Phase: 1/2
- Setting: A Single-arm, Multicenter, Open-label, Phase I/II Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies
- Sponsor: AvenCell Therapeutics, Inc.
- Enrolled: 178

## Sources

- ClinicalTrials.gov NCT07284433: https://clinicaltrials.gov/study/NCT07284433

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07284433.json